Karen S Anderson1, Kristina R Dahlstrom2, Julia N Cheng3, Rizwan Alam3, Guojun Li2, Qingyi Wei4, Neil D Gross2, Diego Chowell5, Marshall Posner6, Erich M Sturgis2. 1. Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States. Electronic address: Karen.Anderson.1@asu.edu. 2. Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 3. Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States. 4. Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, United States. 5. Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States; Simon A. Levin Mathematical, Computational, and Modeling Sciences Center, Arizona State University, Tempe, AZ, United States. 6. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, United States.
Abstract
BACKGROUND: Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. METHODS: IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. RESULTS: HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p<0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). CONCLUSIONS: Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.
BACKGROUND: Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. METHODS: IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. RESULTS:HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p<0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). CONCLUSIONS: Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.
Authors: Karen S Anderson; Sahar Sibani; Garrick Wallstrom; Ji Qiu; Eliseo A Mendoza; Jacob Raphael; Eugenie Hainsworth; Wagner R Montor; Jessica Wong; Jin G Park; Naa Lokko; Tanya Logvinenko; Niroshan Ramachandran; Andrew K Godwin; Jeffrey Marks; Paul Engstrom; Joshua Labaer Journal: J Proteome Res Date: 2010-11-23 Impact factor: 4.466
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Elaine M Smith; Justine M Ritchie; Michael Pawlita; Linda M Rubenstein; Thomas H Haugen; Lubomir P Turek; Eva Hamsikova Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396
Authors: Markus Hoffmann; David Scheunemann; Asita Fazel; Tibor Görögh; Tomas Kahn; Stefan Gottschlich Journal: Oncol Rep Date: 2009-03 Impact factor: 3.906
Authors: Elaine M Smith; Linda M Rubenstein; Justine M Ritchie; John H Lee; Thomas H Haugen; Eva Hamsikova; Lubomir P Turek Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Elaine M Smith; Michael Pawlita; Linda M Rubenstein; Thomas H Haugen; Eva Hamsikova; Lubomir P Turek Journal: Int J Cancer Date: 2010-07-01 Impact factor: 7.396
Authors: Elaine M Smith; Justine M Ritchie; Kurt F Summersgill; Henry T Hoffman; Dong Hong Wang; Thomas H Haugen; Lubomir P Turek Journal: J Natl Cancer Inst Date: 2004-03-17 Impact factor: 13.506
Authors: Morgan A Gingerich; Joshua D Smith; Nicole L Michmerhuizen; Megan Ludwig; Samantha Devenport; Chloe Matovina; Chad Brenner; Steven B Chinn Journal: Head Neck Date: 2018-02-10 Impact factor: 3.147
Authors: Matthew E Spector; Assuntina G Sacco; Emily Bellile; Jeremy M G Taylor; Tamara Jones; Kan Sun; William C Brown; Andrew C Birkeland; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Kelly Malloy; Paul Swiecicki; Avraham Eisbruch; Jonathan B McHugh; Douglas B Chepeha; Laura Rozek; Francis P Worden Journal: Clin Cancer Res Date: 2016-11-21 Impact factor: 12.531
Authors: Ye Tao; Erich M Sturgis; Zhigang Huang; Yan Sun; Kristina R Dahlstrom; Qingyi Wei; Guojun Li Journal: Int J Cancer Date: 2018-05-02 Impact factor: 7.396
Authors: Karen S Anderson; Garrick Wallstrom; Hilde Langseth; Marshall Posner; Julia N Cheng; Rizwan Alam; Diego Chowell; Ingegerd E Furre; Jon Mork Journal: Oral Oncol Date: 2017-09-01 Impact factor: 5.337
Authors: Yuehan Zhang; Tim Waterboer; Michael Pawlita; Elizabeth Sugar; Howard Minkoff; Ross D Cranston; Dorothy Wiley; Robert Burk; Susheel Reddy; Joseph Margolick; Howard Strickler; Kathleen Weber; Maura Gillison; Gypsyamber D'Souza Journal: Cancer Epidemiol Date: 2016-06-23 Impact factor: 2.984
Authors: Yasmin Hasan; Larissa Furtado; Ana Tergas; Nita Lee; Rebecca Brooks; Anne McCall; Daniel Golden; Shruti Jolly; Gini Fleming; Matthew Morrow; Kimberly Kraynyak; Albert Sylvester; Fauzia Arif; Matt Levin; David Schwartz; Jean Boyer; Jeffrey Skolnik; Mark Esser; Rakesh Kumar; Mark Bagarazzi; Ralph Weichselbaum; Michael Spiotto Journal: Int J Radiat Oncol Biol Phys Date: 2020-03-07 Impact factor: 7.038